Immunity Bio (IBRX) is a high-conviction buy due to its 700% revenue growth, successful commercialization of ANKTVA, and strong European regulatory approval, despite significant cash burn.
Source Post
Is Immunitybio Inc IBRX A Good Time To Buy Now? IBRX Stock Analysis
Mar 15, 2026
Immunity Bio (IBRX) is presented as a compelling, high-growth biotech opportunity following a significant commercial inflection. The company has shifted from a science project to a revenue-generating entity, driven by its immunotherapy drug ANKTVA for bladder cancer. Despite a high cash burn, strong gross margins, a fortress balance sheet, and positive regulatory news in Europe and the Middle East support a bullish outlook, with analysts setting aggressive price targets.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
IBRXbuy opened Mar 15, 2026
-16.92%